Transcriptional activation of heat shock protein 27 gene expression by 17β-estradiol and modulation by antiestrogens and aryl hydrocarbon receptor agonists

W Porter, F Wang, R Duan, C Qin, E Castro-Rivera, K Kim and S Safe

Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas 77843–4466, USA

(Requests for offprints should be addressed to S H Safe, Department of Veterinary Physiology and Pharmacology, Texas A&M University, TAMU 4466, College Station, Texas 77843–4466, USA; Email: ssafe@cvm.tamu.edu)

ABSTRACT

Heat shock protein 27 (Hsp 27) is expressed in mammary tumors and may play a role in tumor growth and response to anti-neoplastic drug therapy. 17β-Estradiol (E2) induces Hsp 27 mRNA levels in MCF-7 human breast cancer cells, and we have investigated the comparative inhibitory mechanisms using the aryl hydrocarbon receptor (AhR) agonist, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and the direct-acting antiestrogen ICI 164,384. TCDD inhibited E2-induced Hsp 27 gene expression and analysis of the Hsp 27 gene promoter showed that the inhibitory response was associated with AhR interactions with a pentanucleotide motif at –3 to +2 in the promoter that corresponded to the core sequence of a dioxin responsive element. In contrast, ICI 164,384 induced Hsp 27 gene expression and reporter gene activity in MCF-7 cells and this represents one of the few examples of the estrogen receptor-α (ERα) agonist activity of the ‘pure’ antiestrogen ICI 164,384.

Journal of Molecular Endocrinology (2001) 26, 31–42

INTRODUCTION

High and low molecular weight heat shock proteins (Hsps) have been widely identified in mammalian and non-mammalian cells/tissues and play an important role in maintaining cellular homeostasis and responding to extracellular stimuli (Lindquist & Craig 1988, Ciocca et al. 1993, Jakob & Buchner 1994, Smith et al. 1998). Hsp 27 is a low molecular weight member of the Hsp family and different phosphorylated forms have been widely identified and linked to the biological activity of this protein (Ciocca et al. 1993). Hsp 27 is induced in many cell types in response to stress and there is evidence that this protein may play a role in multiple cellular processes. For example, in murine embryonic stem cells, Hsp 27 prevents differentiating cells from undergoing apoptosis (Ciocca et al. 1993) and studies in other cell lines also show that Hsp 27 blocks apoptotic pathways (Ciocca et al. 1993, Mehlen et al. 1996, 1997, Guenal et al. 1997, Wagstaff et al. 1999).

Hsp 27 is highly expressed in many tumors and cancer cell lines including estrogen receptor (ER)-positive MCF-7 human breast cancer cells and the biological significance and prognostic value of Hsp 27 in mammary tumors has been reported (Ciocca et al. 1983, Tetu et al. 1992, Oesterreich et al. 1993, 1996b, Langdon et al. 1995, Munoz de Toro & Luque 1997, Hsu & Hsu 1998, Arts et al. 1999). In MCF-7 cells stably transfected with human Hsp 27 antisense cDNA, decreased Hsp 27 expression was associated with growth inhibition and cellular hypertrophy (Mairesse et al. 1996). In contrast, induction of Hsp 27 in MCF-7 and other cancer cell lines is associated with increased cell growth and resistance to cytotoxic drugs such as doxorubicin (Oesterreich et al. 1993). Early studies showed a correlation with Hsp 27 and ER expression in breast cancer cells (Adams & McGuire 1985, Horne et al. 1986).
Hsp 27 is induced by heat shock and 17β-E2 in breast cancer cells (Edwards et al. 1980, 1981, Moretti-Rojas et al. 1988, Fuqua et al. 1989, Dunn et al. 1993). Oesterreich and co-workers initially identified estrogen response element (ERE) half-sites, Sp1 and AP-2 binding sites in the E2-responsive proximal region of the Hsp 27 gene promoter (Oesterreich et al. 1996a). They also identified a nuclear matrix protein (HET) that inhibits expression of constructs containing Hsp 27 gene promoter inserts (Oesterreich et al. 1997). Studies in this laboratory identified an Sp1 (N)10ERE half-site motif (Porter et al. 1996) that bound ERα and Sp1 proteins and in transient transfection assays this region of the Hsp 27 gene promoter was E2-responsive. However, subsequent studies showed that only the GC-rich site (Porter et al. 1997) was required for E2-mediated transactivation that involved ERα/Sp1 binding to the GC-rich site in which ERα bound Sp1 protein but not DNA. This ERE-independent pathway for ERα action in breast cancer cells was subsequently characterized in promoters of the c-fos, adenosine deaminase, cathepsin D, insulin-like growth factor binding protein 4, E2F1 and c-Ha-2 genes (Porter et al. 1997, Duan et al. 1998, Sun et al. 1998, Wang et al. 1998, 1999, Dong et al. 1999, Qin et al. 1999, Xie et al. 1999).

Although the precise role of Hsp 27 in breast cancer is unclear, overexpression of this gene is associated with resistance to some cytotoxic drugs. Therefore, this study was initiated to investigate inhibition of E2-induced Hsp 27 gene expression by direct-acting antiestrogens such as ICI 164,384 and aryl hydrocarbon receptor (AhR) agonists through inhibitory AhR-ERα cross-talk. The AhR is a ligand-activated basic helix-loop-helix protein that forms a nuclear heterodimer with the AhR nuclear translocator (Arnt) protein and induces gene expression through interaction with dioxin responsive elements (DREs) in target gene promoters (Swanson & Bradfield 1993, Whitlock 1993, Whitlock et al. 1996). It has been shown that AhR agonists inhibit E2-induced responses in the rodent uterus and mammary tumors and in human breast cancer cell lines (reviewed in Safe 1995 and Safe et al. 1999), and inhibitory DREs (iDRE) have been identified as genomic targets in promoter regions of the E2-responsive cathepsin D, pS2 and c-fos genes (Krishnan et al. 1995, Duan et al. 1999, Gillesby et al. 1997). The results of this study show that, like several other E2-induced genes, AhR agonists block induction of Hsp 27 by interaction with an iDRE in the promoter, whereas ICI 164,384 exhibits ERα agonist activity and this is one of the few examples showing that a ‘pure’ antiestrogen exhibits estrogenic activity.

MATERIALS AND METHODS

Cells, chemicals and biochemicals

MCF-7 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Ah-nonresponsive benzo[a]pyrene-resistant MCF-7 cells (MCF-7BaPr) were derived in this laboratory as previously described (Moore et al. 1994). Cells were maintained in MEM medium with phenol red and supplemented with 10% fetal bovine serum plus 10 ml antibiotic–antimyotic solution (Sigma Chemical Co., St Louis, MO, USA) in an air–carbon dioxide (95:5) atmosphere at 37°C. Prior to their use in this study, MCF-7 BaPr were maintained in 1 μM benzo[a]pyrene for several passages to ensure their Ah-nonresponsiveness as previously described (Moore et al. 1994). Cells were grown in DME-F/12 medium without phenol red and 2.5% dextran/charcoal-stripped fetal bovine serum 2 days before dosing. The human ERα (hERα) expression plasmid (HEG0) was kindly provided by Dr Ming-Jer Tsai (Baylor College of Medicine, Houston, TX, USA), and the variant ERα constructs HE11 (DNA binding domain deficient), HE15 (expressing AF1) and HE19 (expressing AF2) were provided by Professor Chambon (Ilkirch, France) and ER-AF1 containing mutations in AF2 (D538A, E542A, D545A) was provided by Dr Donald McDonnell, Duke University (Durham, NC, USA). ICI 164,384 and 182,780 were obtained from Dr Alan Wakeling (Astra Zeneca, Macclesfield, UK), tamoxifen and 4'-hydroxytamoxifen were purchased from Sigma Chemical Co. TCDD was synthesized in this laboratory and was >99% pure as determined by gas chromatography. Oligonucleotides were synthesized by the Gene Technologies Laboratory, Texas A&M University (College Station, TX, USA). Human AhR antibodies were kindly provided by Dr Carol Holtzapple (USDA Laboratory, College Station, TX, USA). All other chemicals and biochemicals were the highest quality available from commercial sources.
Oligonucleotides and plasmids

The oligonucleotides used in this study are summarized below.

DRE:
5’-GATCTCCGGTCTTTCTCACGCAACGCCTGGGG-3’

mutant DRE:
5’-GATCTCCGGTCTTTCTCACGCAACGCCTGGGG-3’ (mutant iDRE underlined)

For construction of the pHsp27 plasmid, the following two primers were used.

A (sense strand):
5’-GGAGCTTTGAGGGGCGGCC-3’

B (antisense):
5’-GGTCTAGATCAAGAAGTGCGGGGC-3’

For construction of pHsp27.m1 plasmid, the previous antisense primer was replaced by a primer with a mutation in the core DRE sequence (the mutation is underlined).

5’-GGTCTAGATCAAGAAGTGCGGGGC-3’

The PCR condition was 94 °C for 3 min, 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 1 min for 30 cycles and 72 °C for 5 min. The high-fidelity DNA polymerase, Finnzymes Oy from MJ Research, Inc. (Watertown, MA, USA), was used in the PCR reaction. The resultant PCR product was cut with HindIII and XbaI at 37 °C overnight and ligated into pBLCAT3 vector (ATCC). The ligation product was transformed into DH5α competent Escherichia coli cells and confirmed by restriction enzyme mapping and DNA sequencing using Sequitherm cycle sequencing kit from Epicentre Technologies (Madison, WI, USA). pERE3 contained three consensus ERE motifs (GGTCA nnn TGACC) separated by ten nucleotides cloned into pBLTATAACAT as described (Saville et al. 2000).

Northern analysis

The plasmid pUCHS208 containing the Hsp 27 cDNA was purchased from StressGen (Victoria, British Columbia, Canada). The plasmid containing the β-tubulin gene was obtained from ATCC. RNA was extracted from cells treated with the appropriate chemicals by using the acidic guanidinium thiocyanate procedure followed by electrophoresis on a 1:2% formaldehyde agarose gel and transferred to a nylon membrane. The membrane was then exposed to u.v. light for 5 min to cross-link RNA to the membrane and baked at 80 °C for 2 h. The membrane prepared in this manner was prehybridized in a solution containing 0.1% BSA, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 10% dextran sulfate, 1% SDS and 5 × SSPE (0.75 M sodium chloride, 50 nM sodium dihydrogen phosphate, 5 mM EDTA) for 18–24 h at 65 °C and hybridized in the same buffer for 24 h with the 32P-labeled DNA probe (106 c.p.m./ml). The cDNA probes were labeled with [α-32P]CTP using the random primed DNA labeling kit (Boehringer-Mannheim, Indianapolis, IN, USA). The resulting blots were quantitated using a Betagen Betascope 603 blot analyzer (Intelligenetics, Mountain View, CA, USA) and visualized by autoradiography using X-Omat film (Eastman Kodak Co., Rochester, NY, USA). Hsp 27 mRNA levels were standardized against β-tubulin mRNA.

Transient transfection assay

Cultured wild-type MCF-7 or variant MCF-7BaPr cells were transfected by the calcium phosphate method with 10 µg of the appropriate pHsp27 construct plus hER, HE11, HE15, ER-AF1 and HE19 expression plasmid (10 µg) using 100 × 20 mm Falcon culture dishes. Preliminary concentration-dependent studies were carried out using both E2, antiestrogens and TCDD to determine effective concentrations for induction and inhibitory responses; the concentrations were 10 nM E2, 10 nM TCDD and 1 µM concentration for the antiestrogens. After 18 h, the media was changed and the cells were treated with the appropriate chemicals in DMSO for 44 h. Cells were then washed with PBS and scraped from the plates. Cell lysates were prepared in 0-16 ml of 0-25 M Tris–HCl, pH 7-5, by three freeze–thaw–sonication cycles (3 min each). Cell lysates were incubated at 56 °C for 7 min to remove endogenous deacetylase activity. Chloramphenicol acetyl transferase (CAT) activity was determined using 0-2 mCi d-threo-[dichloroacetyl-1-14C] chloramphenicol and 4 mM acetyl-CoA as substrates. The protein concentrations were determined using BSA as a standard. Following TLC, acetylated products were visualized and quantitated using a Betascope 603 Blot analyzer. For most experiments, cells were cotransfected with pCDNA3-1/His/LacZ plasmid (Invitrogen, Carlsbad, CA, USA) and β-galactosidase activity was determined and used to correct for transfection efficiency. Band intensities were also quantitated by densitometry using the Molecular Dynamics Zero-D software package (Molecular Dynamics, Sunnyvale, CA, USA) and a Sharp JX-330 scanner (Mahwah, NJ, USA). CAT activity was calculated as the percentage of that observed in cells treated with DMSO alone and results are expressed as means ± s.d.s. The experiments were carried out at least in triplicate.
u.v.-DNA cross-linking

For cross-linking studies, 10 pmol of the synthetic oligonucleotide (Hsp 27-DRE) was annealed to 10 pmol of a cross-linked primer sequence. The annealed template was end-filled with the Klenow fragment of DNA polymerase in the presence of 0.1 µM dGTP, dATP and bromodeoxyuridine (BrdU) and 1 mM \[^{32}P\]dCTP as previously described (Krishnan et al., 1995, Gillesby et al., 1997) and was designated the BrdU-substituted DRE oligonucleotide. Nuclear extracts (10 µg) from MCF-7 cells treated with appropriate chemicals were incubated with the BrdU-DRE for 15 min at 20 °C following a 15-min incubation at 20 °C with 400 ng of poly(dI-dC) in HEGD buffer (25 mM HEPES, 1.5 mM EDTA, 10% glycerol, 1.0 mM dithiothreitol) for 10 min followed by a 5 min incubation at 20 °C with unlabeled excess competitor. The incubation mixtures were irradiated by using a FOTODYNE u.v. transilluminator at > 205 nm for 30 min at 20 °C. Samples were then mixed with 20 µl of an SDS loading buffer, heated to 95 °C for 5 min and then subjected to electrophoresis on SDS-6% polyacrylamide gels. Molecular weights of u.v. cross-linked nuclear ligand–AhR complexes were calculated from \[^{14}C\]-methylated standards obtained from Amersham Corp. (Arlington Heights, IL, USA). Immunodepletion of the AhR was carried out by incubating 10 µg of nuclear extract with 1 µg of either AhR antibody or mouse IgG for 1 h at 25 °C. The immunodepleted extract was then used in the u.v. cross-linking studies as described above.

Statistics

All data points for transient transfection were repeated at least three times (separate experiments). Results were analyzed by ANOVA and Scheffé’s post hoc test and are presented as means ± s.d.s or s.e.s as indicated.

RESULTS

1. Comparative effects of ER antagonists and TCDD (AhR agonist) on Hsp 27 gene expression induced by E2

Previous studies showed that E2 induced Hsp 27 gene expression 4–24 h after treatment (Porter et al., 1996), and the results illustrated in Fig. 1A show that 10 nM E2 alone induced a 3-2-fold increase in Hsp 27 mRNA levels in MCF-7 cells after hormone treatment for 12 h. The effects of the pure antiestrogen ICI 164,384 (1 µM) alone or in combination with E2 gave surprising results; ICI 164,384 alone (2 or 12 h) induced a 2-3- to 2-6-fold increase in Hsp 27 mRNA levels and in combination with E2 no inhibitory response was observed.

![Figure 1](https://www.endocrinology.org/download/FIGURE1.png)

**FIGURE 1.** Modulation of estrogen-induced Hsp 27 gene expression by antiestrogens and TCDD. (A) Induction by ICI 164,384. Cells were treated with DMSO (lane 1), 10 nM E2 alone for 12 h (lane 6), and 1 µM ICI 164,384 for 2 and 12 h (lanes 2 and 5 respectively). Cells were also co-treated with E2 for 12 h and ICI 164,384 for 2 and 12 h (lanes 3 and 5 respectively). Cell extracts were obtained and total RNA was isolated and subjected to Northern analysis as described under the Materials and Methods section. The intensity values in lanes 2–6 relative to control (lane 1, 100 ± 3%). There was a significant decrease (P < 0.05) in Hsp 27 mRNA levels in the cotreated (E2+iTCDD) cells compared with those treated with E2 alone.

*Journal of Molecular Endocrinology (2001) 26, 31–42*
These results are expressed as means ± s.d.s for three separate determinations, and similar results were obtained in a duplicate experiment (data not shown). The results in Fig. 1B summarize effects of 10 nM TCDD alone, 10 nM E2 alone and their combination on Hsp 27 mRNA levels in MCF-7 cells. In this experiment, 10 nM E2 only caused a 1.8-fold induction of Hsp 27 mRNA levels 24 h after treatment (lane 6), whereas no induction was observed in cells treated with 10 nM TCDD alone for 2 or 24 h (lanes 2 and 4). In contrast, Hsp 27 mRNA levels induced by E2 were significantly inhibited after 2 or 24 h treatment with TCDD. Thus, TCDD but not ICI 164,384 inhibited induction of Hsp 27 gene expression by E2.

2. Interactions of direct-acting antiestrogens and TCDD on E2-induced transactivation in transient transfection assays

pHsp27 contains the E2-responsive −108 to +23 region of the Hsp 27 gene promoter in pBLCAT3, and induction by E2 in MCF-7 cells was observed only after cotransfection with hERα as previously reported for studies using constructs containing other E2-responsive gene promoter inserts (Moore et al. 1994, Krishnan et al. 1995, Porter et al. 1996, 1997, Gillesby et al. 1997, Duan et al. 1998, 1999, Sun et al. 1998, Wang et al. 1998, 1999, Dong et al. 1999, Qin et al. 1999, Xie et al. 1999, Saville et al. 2000). For relatively weak E2-responsive promoters, endogenous ERα levels are insufficient for cells overexpressing the transfected constructs, and transactivation by E2 is observed only after transfection with hER. In MCF-7 cells transfected with pHsp27, 10 nM E2 alone induced a >3-fold increase in CAT activity and 2.5-fold induction was observed for 1 μM ICI 164,384 (Fig. 2A). Previous studies have identified an E2-responsive Sp1(N)10ERE half-site motif in this promoter, and mutation of these sites resulted in loss of induction by E2 (Porter et al. 1996). Ten nM TCDD did not affect CAT activity in MCF-7 cells transfected with pHsp27 compared with solvent (DMSO) control. ICI 164,384 in combination with E2 gave results similar to that observed for the antiestrogen alone and CAT activity was lower than observed for E2 alone. In contrast, cotreatment of MCF-7 cells with TCDD plus E2 resulted in >70% inhibition of hormone-induced activity. The comparative ERα agonist/antagonist activities of tamoxifen, 4'-hydroxytamoxifen and ICI 182,780 were also determined (Fig. 2B), and the three direct-acting antiestrogens all exhibited agonist activities as observed for ICI 164,384 and their antiestrogenic effects were minimal. The effects of direct-acting antiestrogens were also investigated in MCF-7 cells transfected with pHsp27 and wild-type hER or variants HE11, HE19 and HE15 (Fig. 2C). E2, 4'-hydroxytamoxifen and ICI 164,384 induced reporter gene activity in cells cotransfected with wild-type hER; in contrast, E2 (but not antiestrogens) also induced CAT activity in cells transfected with HE11 which contains a deletion of the DNA binding domain of ERα. Ligand-induced transactivation was not observed using HE15 or HE19 that contain a C-terminal deletion of activation function 2 (AF2) and an N-terminal deletion of AF1 respectively. These results for E2 plus hERα and the variant expression plasmids HE11, HE15 and HE19 were similar to those reported using a construct containing a consensus GC-rich promoter insert with a GGCGGG sequence that binds Sp1 protein with high affinity (Saville et al. 2000). The deletion constructs used in this study were derived from human ER (HE0) (Kumar et al. 1986, 1987) containing a G400 V point mutation; however, ongoing studies with wild-type ER (HEG0) variants HEG11 and HEG19 give results that are similar to those observed with HE11 and HE15 (unpublished results). The pure antiestrogens (ICI 164,384 and 182,780) do not induce reporter gene activity in cells transfected with constructs containing ERE-dependent promoters and hER or ER-AF1 (Tzukerman et al. 1994, McDonnell et al. 1995, Yoon et al. 2000), whereas E2 is active using pERE2 and hERα or ER-AF1 expression plasmids (Fig. 2D). Saville and co-workers (2000) reported that ERα/Sp1 activation of a GC-rich promoter in MCF-7 cells was AF1-dependent and induced by E2 and ICI 182,780, and the results in Fig. 2D also show that both E2 and antiestrogens induced CAT activity in cells transfected with pHsp27 and ER-AF1. These results are consistent with the importance of AF1 for estrogen/antiestrogen activation of GC-rich sites (Saville et al. 2000), and we have also observed similar induction with other GC-rich promoters (K Kim, unpublished observations).

3. Identification of a functional iDRE in the Hsp 27 gene promoter

Pentanucleotide GCGTG sequences have previously been identified as functional iDREs in the cathepsin D, c-fos and pS2 gene promoters (Krishnan et al. 1995, Gillesby et al. 1997, Duan et al. 1999), and a similar sequence is present at −3 to +2 in the Hsp 27 gene promoter. The role of this motif in mediating inhibitory AhR-ERα cross-talk was confirmed in MCF-7 cells transiently
transfected with pHsp27 m1 that contains mutation in the pentanucleotide sequence (Fig. 3A). The effects of E2, ICI 164,384, TCDD and E2 plus ICI 164,384 on CAT activity in cells transfected with pHsp27 m1 were similar to those observed for the wild-type construct (Fig. 2); however, in cells cotreated with E2 plus TCDD, the inhibitory effect of TCDD was not observed using the mutant construct. Further confirmation for the role of the AhR in mediating the effects of TCDD was obtained using variant BaBr² MCF-7 cells that express low levels of the AhR and are Ah-nonresponsive (Moore et al. 1994). Transfection studies in this cell line with pHsp27 showed the E2 and ICI 164,384 induced reporter gene activity; however, inhibition of this response was not
observed in cells cotreated with E2 plus TCDD (Fig. 3B).

Direct binding of the AhR complex to the iDRE within the Hsp 27 oligonucleotide was not observed in gel mobility shift assays (data not shown), and this was consistent with results of previous studies showing that AhR complex–iDRE interactions were non-detectable using gel mobility shift assays (Krishnan et al. 1995, Gillesby et al. 1997, Duan et al. 1999). In contrast, results of cross-linking studies using BrdU-substituted [32P]Hsp 27 confirmed interactions between the nuclear AhR complex and the iDRE motif (Fig. 4). Incubation of a BrdU-substituted Hsp 27 oligonucleotide with nuclear extracts from MCF-7 cells treated with TCDD gave a 190 kDa cross-linked band (lanes 3 and 6); the band intensity was decreased by co-incubation with unlabeled DRE (lane 4) but not decreased after co-incubation with unlabeled mutant DRE (lane 5). In a separate experiment
(lanes 6–8), pre-incubation of the nuclear extract with AhR antibodies decreased formation of the 190 kDa cross-linked band (lane 7), whereas pre-incubation with nonspecific IgG did not affect formation of the cross-linked band (lane 8). These results confirm that the AhR complex interacts with the iDRE in the Hsp 27 gene promoter and complements results of previous studies showing that the nuclear AhR complex cross-links with core pentanucleotide iDREs in the cathepsin D, c-fos and pS2 gene promoters (Krishnan et al. 1995, Gillesby et al. 1997, Duan et al. 1999).

DISCUSSION

Hsp 27 is an estrogen-regulated gene in breast cancer cells and there is evidence that this protein plays a role in breast cancer cell growth and drug resistance. Direct-acting antiestrogens such as tamoxifen are used extensively for treatment of breast cancer; however, there is concern that long-term use of tamoxifen increases the risk for endometrial cancer due to the partial ER agonist activity of this drug in the uterus (Jordan 1984, 1993, Cook et al. 1995, Jordan & Assikis 1995, MacGregor & Jordan 1998). New steroidal antiestrogens such as ICI 182,780 and 164,384 have also been developed as antiestrogens that exhibit ER antagonist activities in rodent mammary tumors and uterus, and in human endometrial and breast cancer cell lines (Wakeling et al. 1991, Wakeling 1993, DeFriend et al. 1994, Wakeling & Bowler 1988, Castro-Rivera et al. 1999). Endocrine therapy for breast cancer also includes indirect antiestrogens such as aromatase inhibitors that block estrogen formation in target tissues (Brodie & Santen 1994).

Ligands for the retinoic acid, vitamin D and peroxisome proliferator-activated receptors activate signaling pathways that block estrogen action and various selective modulators are being developed for treatment of breast cancer (Fraker et al. 1984, Colston et al. 1992, Hong & Itri 1994, Elstner et al. 1998). Research in this laboratory has focused on the mechanisms of inhibitory AhR–ER cross-talk and development of selective AhR modulators (SAhRMs) for treatment of breast cancer (Safe 1995, 1999, Porter & Safe 1998, Zacharewski & Safe 1998, Safe et al. 1999). Since Hsp 27 may play an important role in mammary cancer, we have investigated the comparative antiestrogenic activities of the ‘pure’ steroidal antiestrogens ICI 164,384 and TCDD, a prototypical AhR agonist. Previous studies showed that TCDD inhibits E2-induced pS2, cathepsin D, prolactin receptor, c-fos and progesterone receptor gene expression in MCF-7 cells (Harper et al. 1994, Zacharewski et al. 1994, Krishnan et al. 1995, Lu et al. 1996, Gillesby et al. 1997, Duan et al. 1999), and similar results were obtained in this study for Hsp 27 (Fig. 1A). Moreover, inhibition of E2-induced Hsp 27 gene expression by TCDD was also observed using pHsp 27 and a functional iDRE was characterized at the transcription start site (~3 to +2). Functional iDREs have previously been identified in the cathepsin D, c-fos and pS2 gene promoters (Krishnan et al. 1995, Gillesby et al. 1997, Duan et al. 1999), and the results show that the mechanisms of AhR-mediated

FIGURE 4. Cross-linking of the nuclear AhR complex with BrdU-DRE. The BrdU-DRE oligonucleotide was incubated with nuclear extracts from cells treated with DMSO (Ctl) (lane 2), TCDD (lanes 3 and 6) or TCDD in the presence of 100-fold excess of unlabeled wild-type DRE (lane 4) or mutan (mut) DRE (lane 5). Nuclear extracts were pre-incubated with either AhR antibody (AhR Ab) (lane 7) or nonspecific IgG (lane 8). Incubation, cross-linking and electrophoresis of the cross-linked complexes were carried out as described in the Materials and Methods section. The 200 kDa cross-linked (X-linked) AhR complexes (arrow) were visualized by autoradiography. Molecular weights were determined with 14C-labeled protein standards purchased from Amersham Corp. (lane 1).
inhibition of ERα action in breast cancer cells is gene promoter specific. Interaction of the AhR complex at the transcription start site in the Hsp 27 gene promoter inhibits induction by E2 but not basal activity, suggesting that interaction of the DNA-bound ERα–Sp1 complex with other nuclear factors and/or the basal transcription machinery may be blocked. In contrast, inhibitory AhR–ERα cross-talk at iDREs in the c-fos and p52 gene promoters involves quenching or masking at E2-responsive GC-rich and AP1 motifs, whereas AhR complex–iDRE interactions in the cathepsin D gene promoter blocks ERα–Sp1 complex formation at an Sp1(N)₃ERE half-site motif.

The antiestrogenic activities of the steroidal ICI 164,384 and 182,780 have been extensively characterized, and these compounds have been designated as ‘pure’ antiestrogens (Wakeling & Bowler 1988, Wakeling et al. 1991, Wakeling 1993, DeFriend et al. 1994). Conflicting mechanisms of action have been proposed for these compounds (Reese & Katzenellenbogen 1991, Dauvois et al. 1993, Parker 1993, Metzger et al. 1995) and recent studies suggest that their ER antagonist activities are associated with ligand-induced changes in the conformation of ERα that prevent interactions with coactivators and other nuclear proteins required for transactivation (Norris et al. 1999, Paige et al. 1999, Van Den Bemd et al. 1999). The results of our studies on the antiestrogenic activity of ICI 164,384 were unexpected since the pure antiestrogen induced Hsp 27 gene mRNA levels in MCF-7 cells and both steroidal (ICI 164,384 and ICI 182,780) and non-steroidal (tamoxifen/hydroxytamoxifen) antiestrogens were ERα agonists in transient transfection assays using pHsp27 and wild-type ERα (Fig. 2). However, results obtained with wild-type and truncated ERα constructs demonstrate that only E2 activated reporter gene activity in MCF-7 cells transfected with HE11 (a DNA binding domain-deficient variant) and pHsp27 and results similar to those summarized in Fig. 2C were also observed using a construct containing a consensus GC-rich Sp1 binding site motif (Saville et al. 2000). These results indicate important ligand structure-dependent differences in HE11/Sp1 activation, suggesting that interactions with the deleted DNA binding domain of ERα are required for antiestrogen-induced gene expression. These data suggest that activation of the Hsp 27 gene by E2 occurs primarily through ERα/Sp1 action through the GC-rich site, since results obtained using the cathepsin D and transforming growth factor α gene promoters, which also have E2-responsive Sp1(N)₃ERE half-site motifs, show that DNA binding by ERα is required for transactivation (Krishnan et al. 1994, 1995, Vyhlidal et al. 2000). Moreover, ICI 164,384 inhibits induction of cathepsin D gene/gene promoter expression in MCF-7 cells (Krishnan et al. 1994).

ERα interacts with several nuclear proteins that modulate ER action, and these include multiple coactivators that primarily interact with the AF2 domain of ERα (Glass et al. 1997, Zwijsen et al. 1997, Lemon & Freedman 1999, McKenna et al. 1999, Johansson et al. 2000, Resnick et al. 2000, Ying & Lin 2000). For example, both ERα–AP1 and ERα–Sp1 are ligand-activated transcription factor complexes in which ERα does not directly bind DNA but interacts with another DNA-bound transcription factor. However, there are several striking differences in ERα–Sp1 vs ERα–AP1 action. Previous studies show that estrogens and antiestrogens induce gene expression through ERα–Sp1 interactions with GC-rich promoter–reporter constructs in breast, prostate and endometrial cancer cell lines but not in HeLa cells (Saville et al. 2000), and similar results were observed in this study using MCF-7 cells. In contrast, E2 but not tamoxifen or ICI 164,384, induced ERα–AP1-dependent activity in breast cancer cells, whereas estrogens and antiestrogens were agonists for this response in HeLa cells (Webb et al. 1995), and subsequent studies have reported other differences between ERα and ERβ interactions with AP1 or Sp1 (Webb et al. 1995, 1999, Paech et al. 1997, Saville et al. 2000). A recent study showed that ERα–AP1 activation by E2 was associated with AF2-dependent interactions with p160 coactivators, whereas antiestrogen activation utilized different pathways that may involve interactions with corepressors (Webb et al. 1999). Mutations in the AF2 domain of ERα did not affect estrogen or antiestrogen activation of pHsp27 in MCF-7 cells (Fig. 2D), whereas this domain is important for ERα–AP1 action by E2 (Webb et al. 1999).

Thus, our results suggest that some E2-responsive genes activated by ERα–Sp1 interactions with GC-rich promoter elements may also be upregulated by steroidal ‘pure’ antiestrogens such as ICI 164,384. Elgort and co-workers (1996) previously reported that ICI 164,384 and tamoxifen induce retinoic acid receptor α1 gene expression in MCF-7 cells and this is consistent with subsequent identification of three E2-responsive GC-rich sites in the proximal promoter region of this gene (Sun et al. 1998). Thus, there is a concordance between gene expression and transient transfection assays for the induction of Hsp 27 and retinoic acid receptor α1 gene expression by ICI 164,384. However, the presence of E2-responsive GC-rich promoter
elements does not necessarily predict ICI 164,384-inducibility of the corresponding genes. For example, bcl2, c-fos, insulin-like growth factor binding protein 4 and E2F1 gene promoters contain E2-responsive GC-rich motifs (Duan et al. 1998, Dong et al. 1999, Qin et al. 1999, Wang et al. 1999) and steroidal antiestrogens inhibited induction of these genes by E2. The ERα agonist activity of ICI 164,384 appears to be dependent not only on the ligand-induced conformational changes of ERα that facilitate interactions with other transcription factors, but also on promoter context, and current studies are focused on further defining molecular mechanisms of ICI 164,384 action.

ACKNOWLEDGEMENTS

This work was supported by the NIH Grants ES04176 and ES09106 and the Texas Agricultural Experiment Station. S S is a Sid Kyle Professor of Toxicology.

REFERENCES


Van Den Bemd GJ, Kuiper GG, Pols HA & van Leeuwen JP 1999 Distinct effects on the conformation of estrogen receptor α and β by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. *Biochemical and Biophysical Research Communications* **261** 1–5.


**REVISED MANUSCRIPT RECEIVED 24 August 2000**